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Introduction
The development of the normal prostate is regulated
by stromal-epithelial interactions via endocrine and
paracrine factors (mainly androgens, growth factors
and cytokines) [1,2]. Prostate cancer cells shifts from
an androgen-dependent to an androgen-independent
state with a concomitant switch from endocrine/
paracrine to autocrine growth regulation [3]. An
important early event in the development of the neo-
plastic phenotype is the induction of genes involved in
autocrine growth, such as growth factors and its recep-
tors [4,5]. Therefore, an analysis of deregulation of the
functional relationship between autocrine growth fac-
tors and their receptors is essential in determining the
pathogenesis and growth regulation of prostate cancer.
This is emphasized by current evidence obtained from
clinical specimens and in vitro experiments. Various
autocrine loops (EGF/EGFRs, NGF/NGFR,
VEGF/VEGFRs, IGFs/IGFRs and FGFs/FGFRs) have
been postulated as regulators of prostate cancer cells
growth [6-11], however, only the first proposition is
well documented. An increased production of trans-
forming growth factor α (TGFα) was found in several
prostate cancer cell lines, including DU145, and the
addition of anti-EGFR to DU145 cell culture inhibits
cell proliferation [12,13]. Moreover, the use of syn-
thetic inhibitors of EGFR tyrosine kinase inhibited
proliferation of androgen-dependent and androgen-
independent prostate cell lines [14-16]. An increased
level of insulin-like growth factors (IGFs) and vascu-
lar endothelial growth factor (VEGF) was observed in
patients with prostate cancer [8,17,18]. It was pro-
posed that IGFs affect the growth of prostate cells by
activation of EGFR [19] and that VEGF may be an
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autocrine mediator of prostate cell motility and a
paracrine angiogenic factor rather than an autocrine
growth factor [20]. 
Despite many experiments published today, only a
few of them are associated with autocrine regulation
of prostate cancer cells, and the mechanism(s) of
autocrine growth of these cells is far from explana-
tion. We do not know whether the same cancer cell
may be regulated by one or by several autocrine loops.
Determination of the interaction between many
autocrine loops of neoplastic cells may explain the
mechanism of neoplastic growth and resistance of
cancer cells to single tyrosine kinase inhibitors,
observed in anticancer therapy.
A useful tool in the investigations of autocrine
growth regulation of cancer cells is found in inhibitors
of tyrosine kinases [21-23]. A series of small-molecu-
lar compounds known as tyrphostins were recently
developed as tyrosine kinase inhibitors by Levitzki
and Gazit [24]. In the present work, we tested two tyr-
phostins: AG1024 (a selective inhibitor of IGFIR) [25]
and tyrphostin SU1498 (a specific inhibitor of
VEGFR2) [26,27] in the growth regulation of DU145
human prostate cancer cells. 
Materials and methods
Chemicals and reagents. Dulbecco's modified minimal essential
medium (DMEM), Minimal Essential Medium (MEM), Hoechst
No 33258, propidium iodide and tyrosine kinase inhibitors:
AG1024 (IC50=0.4 μM) and SU1498 (IC50=0.7 μM) were pur-
chased from Sigma (St. Louis, Mo., USA). Fetal bovine serum
(FBS) was obtained from Biowest, South American Origin. Other
reagents were provided by POCh (Gliwice, Poland). 
Stock solutions of the tyrphostins were prepared by dissolving
the compounds in dimethylsulfoxide (DMSO) to final concentra-
tion 50 mM and storing the resultant solutions at -20°C.
DMEM/F12 (1:1) medium was used do dilute stock solutions to
working concentrations (0.1-10 μM).
Cell culture. DU145 (HTB-81) cells were obtained from the
American Type Culture Collection (ATCC) and cultured in MEM,
supplemented with 100 IU/ml penicillin and 100 mg/ml strepto-
mycin in the presence of 10% fetal bovine serum (FBS). The cells
were passaged two times per week.
Cell proliferation assay. Target cells were seeded on 96-well
plates at concentrations of 5×103 cells/well in (MEM), supple-
mented with 100 I.U./ml penicillin and 100 mg/ml streptomycin
in the presence of 10% FBS. Following 24 h of incubation, the
culture medium was replaced with serum-free DMEM/F12 (1:1)
supplemented with transferrin (5 mg/ml), sodium selenite
(2ng/ml) and albumin (0.5 mg/ml) [DMEM/F12+]. After addi-
tional 24 h of incubation (Day 0), the medium was replaced with
serum-free DMEM/F12+ medium containing tyrosine kinase
inhibitors: AG1024, SU1498 (0.1-10 μM). The incubation was
continued for the next 48 h at 37°C in humidified atmosphere.
The modified crystal violet staining method (CV) [28] was used
to determine the influence of the tyrphostins on proliferation of
target cells. The absorbance was measured using a Tecan (Spec-
tra Fluor Plus) multiscan plate recorder. Ten replicate wells were
used for each experiment.
The influence of tyrosine kinase inhibitors was expressed as a
relative (to the controls) decrease in cell growth determined after
48 h of incubation with the investigated compounds. The calculat-
ed parameter was:
where: Ao, Ac, Ai - average values of absorbance at 540 nm (CV)
or 570 nm (MTT) of the control sample at the start of experiment
(Ao), control sample after 48 h of incubation (Ac) and after 48 h of
incubation with the investigated inhibitors (Ai). 
Assessment of cell viability. Differential staining method
(Hoechst 33258/PI) was used in the investigation of the effect of
tyrphostins AG1024 and SU1498 on the viability of DU145 cells
[29]. The cells were seeded on 24-well plates at a density 2×104
per well in 0.8 ml MEM with 5% FBS. Following 24 h of incu-
bation, the culture medium was replaced with serum-free
DMEM/F12+ medium. After additional 24 h of incubation, the
cells were exposed to 10 μM concentrations of the investigated
tyrphostins and 50 nM of taxol. The experiment was carried out
for 48 h and then Hoechst No 33258 and propidium iodide were
added to the final concentration of 5 µg/ml and 1 µg/ml, respec-
tively. After 15 min, the cells were directly examined on plates
with a fluorescent Olympus IMT 2 microscope. Two excitation
filters were used: one allowing for excitation of both dyes, the
other - only PI. The Image J software was used for image pro-
cessing (emerging RGB channels, enhancing contrast and sharp-
ening) and the quantitative analysis of the processed pictures
(cell counting). It allowed for estimating the fraction of dead cells
(PI/DNA signal), viable cells (Hoechst 33258/DNA signal), and
apoptotic cells (Hoechst 33258/DNA signal with morphological
changes characteristic of last-phase apoptosis). Each experiment
was repeated at least six times. Images with the number of cells
exceeding approximately 100 were selected for the analysis. 
Cell cycle analysis. To estimate the proportion of cells in various
phases of cell cycle, cellular DNA contents were measured by
flow cytometry (FACS). Cells (8×103/well) were plated on 6-well
plates, in MEM supplemented with 10% FBS and sodium pyru-
vate (MEM-NEAA), and allowed to attach overnight. Subse-
quently, the cells were placed in DMEM/F12+ and incubated for
another 24 h. After this time, 10 μM AG1024 or SU1498 were
added to the investigated cells. Forty-eight h after tyrphostins
addition, the cells were harvested by trypsinization and cen-
trifuged. The pellets were suspended in 0.5 ml of cold PBS and
washed twice. The centrifuged pellets were suspended in 70%
ethanol, fixed at 4°C for 2 h and centrifuged (7 min at 280 × g).
The pellets were then re-suspended in 5 ml of PBS and cen-
trifuged again. The cells were stained with 1 ml of propidium
iodide (PI) solution (0.2 mg of RNAse A, 0.02 mg PI, 1 ml Tri-
ton X-100). Each sample was incubated at 37°C for 30 min. DNA
content was determined by the use of a FACScan Beckton-Dick-
inson flow cytometer. 
Statistical analysis. The statistical analysis was performed with
the use of the Statistica 6 program. The effects of different tyr-
phostins concentrations on DU145 cells proliferation were ana-
lyzed using one way ANOVA, followed by the Dunnett's test.
The Mann Whitney U test was used to determine differences in
the percentage of alive, apoptotic and necrotic cells in the con-
trol sample versus tyrphostins or taxol (paclitaxel) treated sam-
ples. Differences were considered significant at p<0.05. The
mean ± SEM of at least ten replicates (CV) or four replicates
(differential staining method) were used for statistical compari-
son.
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Results
Effect of tyrphostins AG1024 and SU1498 
on DU145 cell proliferation
Human prostate DU145 cells were exposed for 48 h to
tyrosine kinase inhibitors, AG1024 and SU1498, added
at the concentration range of 0.5 - 10 μM. The effect of
the investigated tyrphostins determined by the CV
method is shown in Table 1. The exposure of prostate
cells to tyrphostins AG1024 and SU1498 at concentra-
tion ≥1 μM resulted in a dose-dependent suppression of
proliferation compared to the controls. Both tyrphostins
caused a similar effect on growth inhibition (Gi) of
DU145 cells. The growth of the investigated cells, deter-
mined by the CV method, was practically completely
inhibited at concentration 10 μM, Gi was 107.2 ± 3.75
and 92.7 ± 3.36 for AG1024 and SU1498, respectively. 
A 50% inhibition of the growth of DU145 cells was
determined by fitting a sigmoidal-model of the dose-
dependent effect of the investigated tyrphostin (Fig. 2),
calculated from the equation:
IC50 coefficients calculated from the growth inhibi-
tion curves were 2.19 ± 0.14 μM and 2.42 ± 0.26 μM
for SU1498 and AG1024, respectively. The results
showed a similar cytostatic activity against DU145
cells of both the investigated tyrosine kinase
inhibitors. The anti-proliferative activity was about 6
times lower for AG1024 (IC50=0.4 μM) and 3 times
lower for SU1498 (IC50=0.7 μM) than the enzyme
inhibitory activity of the investigated tyrphostins.
Effect of CM on target cell viability
The investigated tyrosine kinase inhibitors were also
examined for their cytotoxic potential and the ability to
induce tumor cell apoptosis or necrosis. The influence
of tyrphostins AG1024 and SU1498 on target cell via-
bility was assessed after double-staining with Hoechst
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Table 1. The influence of AG1024 (a) and SU1498 (b) on the
autocrine growth of DU145 cells, determined by crystal violet
(CV) method. 
Fig. 1. The dose-dependent effect of tyrphostins: AG1024 (a) and
SU1498 (b) on the growth of DU145 cells after 48 h of incubation
in serum-free DMEM/F12+ medium. 
↑ - statistical significance (compared to control); ↑ - statistical significance
(compared to day "0" [A0]); *** - p < 0.001, ** - 0.01 <p< 0.001, * - 0.05
<p< 0.01, ns - not significant
33258 and propidium iodide. Viable cells were dyed
on blue, apoptotic on light-blue and necrotic cells on
red. Apoptotic cells were clearly distinguishable by
their characteristic morphology (cytoplasmic bleb-
bing, cell shrinkage, nuclear condensation and frag-
mentation) (Fig. 2). The results of quantitative deter-
mination of the number of viable, apoptotic and
necrotic cells are presented in Figure 3. The investi-
gated receptor kinase inhibitors influenced the viabili-
ty of DU145 cells in a similar manner after 48 h of
incubation in the serum-free medium. In the case of
the control culture, the amount of apoptotic and
necrotic cells did not exceed 1.89 ± 0.25% and 0.2 ±
0.1% of the entire cell population. The viability of
DU145 cells cultured with AG1024 and SU1498 was
in the range 91.2 - 91.7% of the entire cell population,
regardless of the kind tyrphostin used. The percentages
of apoptotic cells after incubation with AG1024 and
SU1498 were 7.75 ± 0.73 and 5.81 ± 0.93, respective-
ly. The number of necrotic cells differed from 1.09 ±
0.22% in the case of AG1024 to 2.48 ± 1.05% in the
case of SU1498. The comparison of these results with
the effect of 50 nM taxol (79.55 ± 4.07% of apoptotic
and 14.00 ± 2.99% of necrotic cells) indicates that both
investigated tyrphostins, used in the concentration ≤10
μM are weakly cytotoxic for DU145 cells. These
results were confirmed by the flow cytometry method.
The number of apoptotic and necrotic cells after
DU145 incubation with AG1024 and SU1498 was
similar.
Influence of AG1024 and SU1498 on cell cycle
of DU145 cells.
DNA content of DU145 cells was determined by the
use of a flow cytometer FACScan Beckton-Dickinson
after 48 h of incubation with the investigated com-
pounds. The results are summarized in Table 2. Simi-
lar differences as compared with the control cell cul-
ture were observed after DU145 treatment with both
investigated tyrphostins. An increase in the number of
cells was about 15%, while the fraction of cells syn-
thesizing DNA decreased by about 50%. The propor-
tion of cells in faze G1 to G2 changed from 2.78 (con-
trol) to 4.61 in the case of AG1024 and 4.43 in the case
of SU1498 (Table 2).
Discussion
Understanding the molecular mechanisms that regu-
late prostate cancer growth may help in developing
clinical strategies for the treatment of the disease. Sev-
eral peptide growth factors, including EGF/TGFα,
FGFs, IGFs, PDGF, VEGF and neurotrophins are
known regulators of prostate function [8, 30-33].
Paracrine growth factors secreted by stromal cells and
autocrine growth factors produced by epithelial cells
mediate the development and proliferation of neoplas-
tic human prostate tissue [30,31]. It is now widely
accepted that autocrine growth regulation is at least
partially responsible for metastatic potential of cancer
cells. Suppression of the invasive phenotype is essen-
tial in developing new therapeutic tools to treat
prostate cancer, indicating that androgen-independent
prostate cancer is characterized by an increased
metastatic potential [34]. 
Various approaches have been used to inhibit or
down-regulate neoplastic growth of prostate cancer
using suramin, taxol, genistein, erbstatin, soluble
receptors, pseudo- ligands, monoclonal antibodies for
tyrosine kinase receptors and synthetic receptor tyro-
sine kinase inhibitors [35-39]. 
One of the most effective growth factors for
prostate cancer cells in vivo and in vitro are the mem-
bers of EGF family [6,39], and the inhibitors of EGF
receptors (ErbB1, ErbB2) are used in clinical treat-
ment of prostate cancer [6,40,41]. Autocrine growth
stimulation of DU145 cells by EGF/TGFα is well doc-
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Fig. 2. A typical picture of the cultures of DU145 cells after 48 h of incubation with 10 μM AG1024 (a) and 50 nM of taxol (b). Dark
blue - viable cells, blue (with nuclear fragmentation) - apoptotic cells, red - necrotic cells.
umented [12,13,17]. However, it has been shown that
an acquired resistance to inhibitors of EGFR has been
reported clinically [42]. It has been suggested that the
resistance is associated with increased signaling
through the IGFI receptor [35]. There is still an unre-
solved question whether prostate cancer itself pro-
duces IGFI or the stromal cells provide the peptide.
The results of earlier experiments [8,9] indicated that
DU145 cells showed overexpression of IGFII and
VEGF. These findings in connection with an increased
level of IGFRI and VEGFRs suggested the participa-
tion of IGFRs and VEGFs in autocrine growth regula-
tion of the investigated cells. There was one in vitro
study, which showed that IGFIR antibodies inhibited
DNA synthesis in PC3, but not DU145 cell lines [43];
however, other investigators found that IGFIR anti-
body prevents proliferation of both the prostate cell
lines [44]. Although an association may exist between
IGFI and prostate cancer, direct causality has not been
established [45]. Another question is the role of
VEGFR in autocrine growth regulation of prostate
cells. Several investigations indicated that VEGF is
mainly the angiogenic and chemotactic factor for
prostate cancer cells; however, it may regulate tumor
growth in vitro [20]. 
We have determined whether blockade of IGFIR or
VEGF2R signaling pathways inhibits autocrine
growth and viability of DU145 cells in vitro. Our
results indicate that each of the investigated tyr-
phostins at concentration >5 μM is able to completely
inhibit DU145 autocrine cell growth. These results
suggest that the two growth factor receptors (IGFIR,
VEGFR2) induce a specific signaling route, or activa-
tion of one of the investigated receptors influences the
mitogenic pathway of the other. The cytostatic poten-
tial of AG1024 (IC50=2.2 μM) and SU1498 (IC50=2.4μM) is almost the same. The data on enzymatic speci-
ficity of the investigated tyrphostins indicate a differ-
ent affinity of the tyrphostins to their now-specific
tyrosine kinase receptors. A comparison of IC50 values
of anti-proliferative and enzyme inhibitory activities
(6:1) of AG1024 suggests that the true ligand for
IGFIR of DU145 cells is IGFII rather than IGFI, and
supports the hypothesis of IGFII/IGFIR autocrine loop
in this type of cancer prostate cells [46]. In the case of
VEGF receptors, our data (in comparison with the
known enzyme inhibitory activity of VEGFR2) indi-
cate the participation of VEGFR1 or/and VEGFR3 in
signal transduction induced by VEGF, secreted by
DU145 cells.
Differential staining method showed that the inves-
tigated tyrphostins, used at concentration ≤10 μM, had
little direct cytotoxity on DU145 cell line. The per-
centage of viable cells after 48 h of incubation with
AG1024 (91.2%) and SU1498 (91.7%) was almost the
same. The number of apoptotic cells varied from 5.8%
for SU1498 to 7.7% for AG1024, and was much lower
than that determined for 50 nM of taxol (79.6%). The
results of double-staining methods were confirmed by
the binding of FITC-labeled Annexin V and exclusion
of propidium iodide (PI), followed by an analysis with
a FACScan flow cytometer (Becton-Dickinson). The
number of viable DU145 cells after treatment with the
investigated tyrphostins did not differ from that deter-
mined in the control culture (data not shown). These
findings indicate that the inhibitory effect of AG1024
and SU1498 is mediated by a cytostatic rather than a
cytotoxic mechanism, and differs from the pro-apop-
totic effect of EGFR kinase inhibitor ZD1839 [6,16].
Further experiments have revealed that both the
investigated inhibitors increased the percentage of
DU145 cells in S phase of cell cycle, indicating that
AG1024 and SU1498 arrest cell growth in G1 phase,
similarly as known inhibitors of EGFR [6,15].
The results of our investigations show that
autocrine growth of DU145 my be regulated, at least,
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Fig. 3. The effect of tyrphostins: AG1024, SU1498 and taxol (as
the positive control) on the induction of apoptosis in DU145 cells,
after 48 h of incubation in DMEM/F12+ medium. The average
percentage of: viable cells (black), apoptotic cells (white) and
necrotic cells (grey). 
*** - p<0,001; ** - 0,001<p<0,01; * - 0,01<p<0,05; ns - not sig-
nificant.
Table 2. The effect of AG1024 and SU1498 on the proportion of
DU145 cells in various phases of cell cycle. Cellular DNA con-
tents were measured by flow cytometry (FACS) after 48 h of incu-
bation with the tyrphostins.
by additional two autocrine loops: IGFII/IGFIR and
VEGF/VEGFRs, despite the well-documented TGF
(EGF)/EGFR loop. Multifactor regulation of autocrine
growth of metastatic cancer cell lines DU145 may can
explain a failure of employing single specific tyrosine
kinase inhibitors in therapy (monotherapy) of prostate
cancer [17,47]. A role for an autocrine growth loop
involving tyrosine kinases and their receptors in tumor
progression has been suggested for a variety of can-
cers. Identifying biologically and physiologically
important autocrine growth events may have important
clinical consequences, also for the introduction of a
new strategies in anticancer therapies.
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